BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 26471695)

  • 21. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
    Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
    J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours.
    Łapińska G; Bryszewska M; Fijołek-Warszewska A; Kozłowicz-Gudzińska I; Ochman P; Sackiewicz-Słaby A
    Nucl Med Rev Cent East Eur; 2011; 14(1):16-20. PubMed ID: 21751167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
    Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
    Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
    Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
    J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
    Haug AR; Rominger A; Mustafa M; Auernhammer C; Göke B; Schmidt GP; Wängler B; Cumming P; Bartenstein P; Hacker M
    J Nucl Med; 2011 Nov; 52(11):1679-83. PubMed ID: 21976529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin.
    Alonso O; Rodríguez-Taroco M; Savio E; Bentancourt C; Gambini JP; Engler H
    Ann Nucl Med; 2014 Aug; 28(7):638-45. PubMed ID: 24862238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
    Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
    Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
    Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
    Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
    Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroendocrine Tumor Diagnosis and Management:
    Sanli Y; Garg I; Kandathil A; Kendi T; Zanetti MJB; Kuyumcu S; Subramaniam RM
    AJR Am J Roentgenol; 2018 Aug; 211(2):267-277. PubMed ID: 29975116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
    Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The significance of incidental brain uptake on 68Ga-DOTATATE PET-CT in neuroendocrine tumour patients.
    Cleary JO; Yeung J; McMeekin H; Wilhelm T; Wagner T
    Nucl Med Commun; 2016 Nov; 37(11):1197-205. PubMed ID: 27399848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.
    Ilhan H; Fendler WP; Cyran CC; Spitzweg C; Auernhammer CJ; Gildehaus FJ; Bartenstein P; Angele MK; Haug AR
    Ann Surg Oncol; 2015 Jan; 22(1):164-71. PubMed ID: 25190113
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Tierney JF; Kosche C; Schadde E; Ali A; Virmani S; Pappas SG; Poirier J; Keutgen XM
    Surgery; 2019 Jan; 165(1):178-185. PubMed ID: 30415869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.